Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors

Rongshi Li, Mathew P. Martin, Yan Liu, Binglin Wang, Ronil A. Patel, Jin Yi Zhu, Nan Sun, Roberta Pireddu, Nicholas J. Lawrence, Jiannong Li, Eric B. Haura, Shen Shu Sung, Wayne C. Guida, Ernst Schonbrunn, Said M. Sebti

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC 50 = 650 nM) and ROCK2 (IC 50 = 670 nM), whereas compound 24 was more selective for ROCK2 (IC 50 = 100 nM) over ROCK1 (IC 50 = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.

Original languageEnglish (US)
Pages (from-to)2474-2478
Number of pages5
JournalJournal of Medicinal Chemistry
Volume55
Issue number5
DOIs
Publication statusPublished - Mar 8 2012

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Li, R., Martin, M. P., Liu, Y., Wang, B., Patel, R. A., Zhu, J. Y., ... Sebti, S. M. (2012). Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. Journal of Medicinal Chemistry, 55(5), 2474-2478. https://doi.org/10.1021/jm201289r